The DOI matches its Crossref record.
Causality assessment: Which is best-expert opinion or RUCAM?
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, disadvantages of the RUCAM scale include complexity and ambiguous instructions, arbitrary weighting of the criteria such as an overestimation of rechallenge, which is seldom done, lack of evidence‐based risk factors, failure to consider ultra‐short or long latency periods for drugs with short or long half‐lives, excessive penalty for concomitant hepatotoxic drugs, or omissions such as”
From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 38
- Zimmerman HJ Hepatotoxicity. The adverse effect of drugs and other chemicals on the liver 2nd edition Philadelphia, PA Lippincott Williams & Wilkins 1999
- Temple, 2006, Hy's Law: Predicting serious hepatotoxicity, Pharmacoepidemiol Drug Saf, 15, 241, 10.1002/pds.1211 · DOI · Paper page
- Lewis, 2013, Drug-induced liver injury throughout the drug development life cycle: where we have been, where we are now, and where we are headed, Perspectives of a clinical hepatologist. Pharmaceutical Med, 27, 165
- Standardization of definitions and criteria of causality assessment of adverse drug reactions, 1990, Drug-induced liver disorders: report of an international consensus meeting, Int J Clin Pharmacol Ther Toxicol, 28, 317
- Danan, 1993, Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries, J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
- Benichou, 1993, Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge, J Clin Epidemiol, 46, 1331, 10.1016/0895-4356(93)90102-7 · DOI · Paper page
- Shapiro, 2007, Causality assessment of drug-induced hepatotoxicity: promises and pitfalls, Clinical Liver Disease, 11, 477, 10.1016/j.cld.2007.06.003 · DOI
- Garcia-Cortes, 2008, Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury, Aliment Pharmacol Ther, 27, 780, 10.1111/j.1365-2036.2008.03655.x · DOI · Paper page
- Teschke, 2013, Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods, World J Gastroenterol, 19, 2864, 10.3748/wjg.v19.i19.2864 · DOI · Paper page
- Garcia-Cortes, 2011, Causality assessment methods in drug induced liver injury: strengths and weaknesses, J Hepatol, 55, 683, 10.1016/j.jhep.2011.02.007 · DOI · Paper page
- Corsini, 2012, Current challenges and controversies in drug-induced liver injury, Drug Saf, 35, 1099, 10.1007/BF03261997 · DOI
- Lucena, 2008, Assessment of drug-induced liver injury in clinical practice, Fundam Clin Pharmacol, 22, 141, 10.1111/j.1472-8206.2008.00566.x · DOI
- Kaplowitz, 2001, Causality assessment versus guilt-by-association in drug hepatotoxicity, Hepatology, 33, 308, 10.1053/jhep.2001.21083 · DOI
- Hawkins, 2012, Latest advances in predicting DILI in human subjects: focus on biomarkers, Expert Opin Drug Metab Toxicol, 8, 1521, 10.1517/17425255.2012.724060 · DOI
- Schomaker, 2013, Assessment of emerging biomarkers of liver injury in human subjects, Toxicol Sci, 132, 276, 10.1093/toxsci/kft009 · DOI
- Antoine, 2013, Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital, Hepatology, 58, 777, 10.1002/hep.26294 · DOI · Paper page
- Lucena, 2001, Comparison of two clinical scales for causality assessment in hepatotoxicity, Hepatology, 33, 123, 10.1053/jhep.2001.20645 · DOI · Paper page
- Sgro, 2002, Incidence of drug-induced injuries: a French population-based study, Hepatology, 36, 451, 10.1053/jhep.2002.34857 · DOI · Paper page
- Lewis, 2008, Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran, Int J Clin Pharmacol Ther, 46, 327, 10.5414/CPP46327 · doi:10.5414/cpp46327
- Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel Uclaf Causality Assessment Method, Hepatology, 51, 2117, 10.1002/hep.23577 · DOI · Paper page
- Graham, 2003, Troglitazone-induced liver failure: a case study, Am J Med, 114, 299, 10.1016/S0002-9343(02)01529-2 · DOI · Paper page
- Fontana, 1999, Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group, Liver Transpl Surg, 5, 480, 10.1002/lt.500050607 · DOI
- Brinker, 2009, Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases, Hepatology, 49, 250, 10.1002/hep.22620 · DOI
- Robles-Diaz, 2014, Use of Hy's Law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury, Gastroenterology, 10.1053/j.gastro.2014.03.050 · DOI · Paper page
- Lewis, 2012, MacSween's Pathology of the liver, 645, 10.1016/B978-0-7020-3398-8.00013-1 · DOI
- Kleiner, 2014, Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations, Hepatology, 59, 661, 10.1002/hep.26709 · DOI · Paper page
- Gupta, 2008, Review article: the use of potentially hepatotoxic drugs in patients with liver disease, Aliment Pharmacol Ther, 28, 1021, 10.1111/j.1365-2036.2008.03822.x · DOI
- Lewis, 2013, Review article: prescribing medications in patients with cirrhosis-a practical guide, Aliment Pharmacol Ther, 37, 1132, 10.1111/apt.12324 · DOI · Paper page
- Lammert, 2010, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events, Hepatology, 51, 615, 10.1002/hep.23317 · DOI
- Chen, 2013, High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
- Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI · Paper page
- Bell, 2012, Serum proteomic profiling in patients with drug-induced liver injury, Aliment Pharmacol Ther, 35, 600, 10.1111/j.1365-2036.2011.04982.x · DOI
- Steuerwald, 2013, Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance, PLoS One, 8, e81974, 10.1371/journal.pone.0081974 · DOI
- Daly, 2013, Pharmacogenomics of adverse drug reactions, Genome Med, 5, 5, 10.1186/gm409 · DOI
- Hoofnagle, 2013, LiverTox: a website on drug-induced liver injury, Hepatology, 57, 873, 10.1002/hep.26175 · DOI · Paper page
- Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI · Paper page
- Davern, 2011, Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury, Gastroenterology, 141, 1665, 10.1053/j.gastro.2011.07.051 · DOI · Paper page
- Watkins, 2013, Managing the risk of drug-induced liver injury, Clin Pharmacol Ther, 94, 629, 10.1038/clpt.2013.182 · DOI
Cited by
Teschke, R., & Eickhoff, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00072 · Cited by 132
Drug-induced liver injury: Highlights from a review of the 2015 literature
Sarges, P., Steinberg, J. M., & Lewis, J. H. (2016) · Drug Safety · doi:10.1007/s40264-016-0427-8 · Cited by 74
Self-citationDakhoul, L., Ghabril, M., Gu, J., Navarro, V., Chalasani, N., & Serrano, J. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.036 · Cited by 36
Shahbaz, O., Mahajan, S., & Lewis, J. H. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1362391 · Cited by 30
Self-citationThe development of a database for herbal and dietary supplement induced liver toxicity
Zhu, J., Seo, J.-E., Wang, S., Ashby, K., Ballard, R., Yu, D., Ning, B., Agarwal, R., Borlak, J., Tong, W., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102955 · Cited by 29
Metadata
- Authors
- Lewis, J. H.
- Affiliations
- Division of Gastroenterology and Hepatology; Georgetown University Hospital; Washington DC
- Venue
- Clinical Liver Disease
- Published
- 2014-07
- Volume
- 4
- Issue
- 1
- Pages
- 4-8
- ISSN
- 2046-2484
- Cited by
- 21
- References
- 0
- Language
- en
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 427 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Causality assessment: Which is best-expert opinion or RUCAM? https://app.cochat.ai/papers/10.1002/cld.365
- The paper
- Lewis, J. H. (2014). Causality assessment: Which is best-expert opinion or RUCAM? Clinical Liver Disease. https://doi.org/10.1002/cld.365
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.